Knight Therapeutics (GUD) investor relations material

Business overview and growth

• Focuses on acquiring or in-licensing innovative pharmaceutical products for Canada and Latin America, with over $685M raised in equity since 2014 and a portfolio exceeding 150 products and 20 partners.

• Achieved a 17% adjusted revenue CAGR and 34% adjusted EBITDA CAGR over five years, with significant expansion through acquisitions such as Grupo Biotoscana, Paladin, and Sumitomo.

• 2025 adjusted revenues reached $452M, up 24% from 2024, and adjusted EBITDA was $73M, up 26% year-over-year.

• Operates in 11 countries, with Canada and Brazil as major revenue contributors, and maintains a pipeline expected to generate over $200M in future revenues.

Strategic acquisitions and product launches

• Acquired Paladin (40+ products, $70M 2024 revenue) and Sumitomo (6 products, $11.2M TTM revenue), adding over 45 products and $80M in annual sales.

• Recent launches include Xcopri (epilepsy), Wynzora (psoriasis), Myfembree (menstrual bleeding/endometriosis), and Orgovyx (prostate cancer), with strong post-acquisition growth.

• Executed 13 launches in 2024–2025 and expects at least 10 launches in 2026, targeting annual peak sales of over $100M from new products.

Financial performance and capital structure

• 2026 revenue guidance is $490–$510M, with adjusted EBITDA margin guidance of ~15%.

• Maintains a healthy balance sheet: $95.3M in cash and marketable securities, $98.4M in financial assets, $67.9M in debt, and a debt-to-equity ratio of 0.36:1.

• Over $250M invested in share buybacks (NCIB), representing more than 30% of shares outstanding.

• Market capitalization stands at $598M with 98M shares outstanding and 23.2% insider holdings.